Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640334 | 0.84 | MAPT (0.54) | MAPTTSHRMAPK1CASP1CASP7 | |
| SCHEMBL16640333 | 0.84 | MAPT (0.54) | MAPTTSHRMAPK1CASP1CASP7 | |
| SCHEMBL16640322 | 0.81 | MAPT (0.41) | MAPTTSHRMAPK1CASP1CASP7 | |
| SCHEMBL16640325 | 0.81 | CCNA2 (0.46) | MAPTTSHRMAPK1CASP1CASP7 | |
| SCHEMBL18237637 | 0.79 | MAPT (0.61) | MAPTTSHRMAPK1CASP1CASP7 | |
| SCHEMBL2628324 | 0.77 | FEN1 (0.47) | MAPTL3MBTL1HSP90AA1NPC1LMNA | |
| SCHEMBL24835421 | 0.76 | MAPT (0.38) | MAPTTSHRMAPK1CASP1CASP7 | |
| SCHEMBL16640331 | 0.76 | USP2 (0.43) | MAPTTSHRMAPK1CASP1CASP7 | |
| SCHEMBL16640342 | 0.76 | CDK4 (0.41) | MAPTTSHRMAPK1CASP1CASP7 | |
| SCHEMBL16640349 | 0.76 | USP2 (0.43) | MAPTTSHRMAPK1CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11189808-B2 | Platinum complexes and devices | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200152891-A1 | PLATINUM COMPLEXES AND DEVICES | UNIV ARIZONA STATE (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-9947881-B2 | Platinum complexes and devices | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170012224-A1 | PLATINUM COMPLEXES AND DEVICES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-01-12 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-9385329-B2 | Platinum complexes and devices | Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105556-A1 | PLATINUM COMPLEXES AND DEVICES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11189808-B2 | Platinum complexes and devices | OXA1L, OCIAD1, OCIAD2 | MAPT 1431/4885TSHR 3038/4885MAPK1 3673/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MAPT 1162/4885TSHR 2393/4885MAPK1 4565/4885 |
| US-20200152891-A1 | PLATINUM COMPLEXES AND DEVICES | OXA1L, OCIAD1, OCIAD2 | MAPT 1431/4885TSHR 3038/4885MAPK1 3673/4885 |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MAPT 1162/4885TSHR 2393/4885MAPK1 4565/4885 |
| US-20170012224-A1 | PLATINUM COMPLEXES AND DEVICES | OXA1L, OCIAD1, OCIAD2 | MAPT 1431/4885TSHR 3038/4885MAPK1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.